Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

DM. Kaye, MC. Petrie, S. McKenzie, G. Hasenfuβ, F. Malek, M. Post, RN. Doughty, JN. Trochu, F. Gustafsson, I. Lang, A. Kolodziej, R. Westenfeld, M. Penicka, M. Rosenberg, J. Hausleiter, P. Raake, G. Jondeau, MW. Bergmann, T. Spelman, H. Aytug, P....

. 2019 ; 6 (1) : 62-69. [pub] 20181011

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012273

AIMS: Impaired left ventricular diastolic function leading to elevated left atrial pressures, particularly during exertion, is a key driver of symptoms and outcomes in heart failure with preserved ejection fraction (HFpEF). Insertion of an interatrial shunt device (IASD) to reduce left atrial pressure in HFpEF has been shown to be associated with short-term haemodynamic and symptomatic benefit. We aimed to investigate the potential effects of IASD placement on HFpEF survival and heart failure hospitalization (HFH). METHODS AND RESULTS: Heart failure with preserved ejection fraction patients participating in the Reduce Elevated Left Atrial Pressure in Patients with Heart Failure study (Corvia Medical) of an IASD were followed for a median duration of 739 days. The theoretical impact of IASD implantation on HFpEF mortality was investigated by comparing the observed survival of the study cohort with the survival predicted from baseline data using the Meta-analysis Global Group in Chronic Heart Failure heart failure risk survival score. Baseline and post-IASD implant parameters associated with HFH were also investigated. Based upon the individual baseline demographic and cardiovascular profile of the study cohort, the Meta-analysis Global Group in Chronic Heart Failure score-predicted mortality was 10.2/100 pt years. The observed mortality rate of the IASD-treated cohort was 3.4/100 pt years, representing a 33% lower rate (P = 0.02). By Kaplan-Meier analysis, the observed survival in IASD patients was greater than predicted (P = 0.014). Baseline parameters were not predictive of future HFH events; however, poorer exercise tolerance and a higher workload-corrected exercise pulmonary capillary wedge pressure at the 6 months post-IASD study were associated with HFH. CONCLUSIONS: The current study suggests IASD implantation may be associated with a reduction in mortality in HFpEF. Large-scale ongoing randomized studies are required to confirm the potential benefit of this therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012273
003      
CZ-PrNML
005      
20190411115324.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ehf2.12350 $2 doi
035    __
$a (PubMed)30311437
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kaye, David M $u Department of Cardiology, Alfred Hospital, Commercial Rd, Melbourne, Victoria, 3004, Australia.
245    10
$a Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction / $c DM. Kaye, MC. Petrie, S. McKenzie, G. Hasenfuβ, F. Malek, M. Post, RN. Doughty, JN. Trochu, F. Gustafsson, I. Lang, A. Kolodziej, R. Westenfeld, M. Penicka, M. Rosenberg, J. Hausleiter, P. Raake, G. Jondeau, MW. Bergmann, T. Spelman, H. Aytug, P. Ponikowski, C. Hayward, . ,
520    9_
$a AIMS: Impaired left ventricular diastolic function leading to elevated left atrial pressures, particularly during exertion, is a key driver of symptoms and outcomes in heart failure with preserved ejection fraction (HFpEF). Insertion of an interatrial shunt device (IASD) to reduce left atrial pressure in HFpEF has been shown to be associated with short-term haemodynamic and symptomatic benefit. We aimed to investigate the potential effects of IASD placement on HFpEF survival and heart failure hospitalization (HFH). METHODS AND RESULTS: Heart failure with preserved ejection fraction patients participating in the Reduce Elevated Left Atrial Pressure in Patients with Heart Failure study (Corvia Medical) of an IASD were followed for a median duration of 739 days. The theoretical impact of IASD implantation on HFpEF mortality was investigated by comparing the observed survival of the study cohort with the survival predicted from baseline data using the Meta-analysis Global Group in Chronic Heart Failure heart failure risk survival score. Baseline and post-IASD implant parameters associated with HFH were also investigated. Based upon the individual baseline demographic and cardiovascular profile of the study cohort, the Meta-analysis Global Group in Chronic Heart Failure score-predicted mortality was 10.2/100 pt years. The observed mortality rate of the IASD-treated cohort was 3.4/100 pt years, representing a 33% lower rate (P = 0.02). By Kaplan-Meier analysis, the observed survival in IASD patients was greater than predicted (P = 0.014). Baseline parameters were not predictive of future HFH events; however, poorer exercise tolerance and a higher workload-corrected exercise pulmonary capillary wedge pressure at the 6 months post-IASD study were associated with HFH. CONCLUSIONS: The current study suggests IASD implantation may be associated with a reduction in mortality in HFpEF. Large-scale ongoing randomized studies are required to confirm the potential benefit of this therapy.
650    _2
$a senioři $7 D000368
650    _2
$a síňový tlak $x fyziologie $7 D062185
650    _2
$a srdeční katetrizace $x metody $7 D006328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a srdeční síně $x patofyziologie $x chirurgie $7 D006325
650    _2
$a srdeční selhání $x mortalita $x patofyziologie $x chirurgie $7 D006333
650    _2
$a hospitalizace $x trendy $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    12
$a protézy a implantáty $7 D019736
650    _2
$a tepový objem $x fyziologie $7 D013318
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a časové faktory $7 D013997
650    _2
$a funkce levé komory srdeční $x fyziologie $7 D016277
651    _2
$a Austrálie $x epidemiologie $7 D001315
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a Nový Zéland $x epidemiologie $7 D009520
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Petrie, Mark C $u University of Glasgow, Glasgow, UK.
700    1_
$a McKenzie, Scott $u Department of Cardiology, Prince Charles Hospital, Brisbane, Australia.
700    1_
$a Hasenfuβ, Gerd $u Georg-August-Universität Göttingen, Göttingen, Germany.
700    1_
$a Malek, Filip $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Post, Martijn $u St Antonius Ziekenhuis Nieuwegein, Nieuwegein, The Netherlands.
700    1_
$a Doughty, Robert N $u University of Auckland, Auckland, New Zealand.
700    1_
$a Trochu, Jean-Noël $u CHU de Nantes, Nantes, France.
700    1_
$a Gustafsson, Finn $u Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Lang, Irene $u Allgemeines Krankenhaus Universitätskliniken, Vienna, Austria.
700    1_
$a Kolodziej, Adam $u Fourth Military Hospital, Wrocław, Poland.
700    1_
$a Westenfeld, Ralf $u Universitätklinikum Düsseldorf, Düsseldorf, Germany.
700    1_
$a Penicka, Martin $u Cardiovascular Center Aalst, Aalst, Belgium.
700    1_
$a Rosenberg, Mark $u University Medical Center Schleswig-Holstein, Kiel, Germany.
700    1_
$a Hausleiter, Jörg $u Klinikum Großhadern, Munich, Germany.
700    1_
$a Raake, Philip $u Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Jondeau, Guillaume $u Bichat AP-HP Hospital, INSERM, Paris, France.
700    1_
$a Bergmann, Martin W $u Cardiologicum Hamburg, Hamburg, Germany.
700    1_
$a Spelman, Tim $u Synergus AB, Stockholm, Sweden.
700    1_
$a Aytug, Huseyin $u Synergus AB, Stockholm, Sweden.
700    1_
$a Ponikowski, Piotr $u Wrocław Medical University, Wrocław, Poland.
700    1_
$a Hayward, Chris $u Department of Cardiology, St Vincent's Hospital, Sydney, Australia.
700    1_
$a ,
773    0_
$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 6, č. 1 (2019), s. 62-69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30311437 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411115341 $b ABA008
999    __
$a ok $b bmc $g 1391583 $s 1050578
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 6 $c 1 $d 62-69 $e 20181011 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace